China-Singapore Jingwei, March 15th (Wu Xiaowei) Amy, have you brightened your eyes?

　　According to the "2021 Medical Beauty Industry White Paper" released by the New Oxygen Data Research Institute, it is expected that the number of medical beauty users will exceed 20 million in 2022.

The research report of CITIC Construction Investment predicts that the scale of China's medical beauty market is expected to exceed 300 billion yuan in 2024. In the medium and long term, there is still room for growth of more than 5 times.

　　However, according to the data from Tianyancha, 8.8% of medical and beauty-related companies have experienced abnormal operations, more than 7,700 medical and beauty-related companies have been administratively punished, and more than 400 related companies have committed serious illegal acts.

According to incomplete statistics, in 2021, my country's medical and beauty-related enterprises will generate more than 1,400 pieces of information about persons subject to enforcement and more than 2,800 pieces of information about legal proceedings.

million dollar compensation

　　The size of IPO funds raised in 2022 will continue to grow on the basis of last year's high growth.

However, since the beginning of the year, no IPO of medical beauty companies has been seen in the domestic market.

　　In October 2021, among the 10 cases of unfair competition in the medical beauty market exposed by the State Administration for Market Regulation, false publicity of doctor qualifications, false publicity of medical and cosmetic product efficacy, service efficacy, and false publicity efficacy etc. shocking.

　　Among them, it was mentioned that Zhejiang Taizhou Yixing Medical Beauty Hospital Co., Ltd. used false cases to commercialize itself and was fined 250,000 yuan.

　　As early as 2018, when Yixing Medical Beauty hit the Hong Kong Stock Exchange, it disclosed in its prospectus that the company had 30 medical advertising violations, 4 medical malpractice cases and 77 portrait rights disputes, including 72 cases that had already passed the payment of the total compensation agreement. 2.6 million yuan to resolve disputes.

The 5 unresolved portrait disputes claimed a compensation amount of 713,500 yuan.

In recent years, Yixing Medical Beauty’s expenditure on fines and disputes has continued to rise. In 2017, the expenditure in this area reached 3.31 million yuan, a year-on-year increase of 59%.

　　Due to the delay in progress, Yixing had to withdraw the listing application materials one year after submitting the form.

　　Hangzhou resident Chen Yan once complained to the media that he spent 37,000 yuan on a nose plastic surgery at Hangzhou Yixing Medical Beauty Hospital.

After the operation, she believed that the prosthesis and the hospital advertised "the goods are not right".

However, the feedback given by the hospital is that all plastic materials are legal and compliant, and there is no possibility that the goods are wrong.

The two sides are already coordinating and communicating.

　　Yimeier Medical, which has hit the Hong Kong stock market listing, also disclosed that from 2018 to the end of the first quarter of 2021, Yimeier experienced 23 medical disputes, and paid a total of 2.1 million yuan in compensation, of which 300,000 yuan was paid in the first quarter of 2021. Yuan.

　　According to reports, in the past five years, there have been at least 6 medical and aesthetic accidents at the Yimeier Guobin Plastic Surgery Hospital in Qingdao.

Among them, in 2020, a consumer spent more than 40,000 yuan. After a complete cosmetic surgery, cysts and pimples appeared on the face and neck.

After the operation, the consumer spent another 7,000 yuan for resection, but the hospital only offered to perform repair surgery for the user free of charge.

　　From the perspective of the capital market, Immel was briefly listed on the New Third Board in 2016, but terminated the listing four months later.

　　From the performance point of view, Immel is hardly optimistic.

From 2018 to 2020, Yimeier's revenue was 661 million yuan, 739 million yuan and 811 million yuan, respectively, with gross profit margins of 53.7%, 51.6% and 53.6%, slightly lower than the industry average of 58.72%.

　　At the same time, the prospectus also disclosed Emel’s losses from March 2018 to 2021.

From 2018 to 2019, the amount of loss expanded from 100 million yuan to 118 million yuan, and within three years, the cumulative loss was 200 million yuan.

　　However, in response to the failure of the listing application, the relevant person in charge of Yimeier responded to the media that the failure is normal and has been common since the second half of last year.

The submitted information is valid for half a year, and after that, additional information needs to be submitted to the Stock Exchange to continue the application.

　　Like Yimeier, the medical and beauty institutions that have stayed on the New Third Board include Lido Plastic Surgery, Spring Medical Beauty, Baihui Medical, etc., but they have all been delisted.

Regulations are gradually tightening

　　On November 2, 2021, the State Administration for Market Regulation issued the "Guidelines for Law Enforcement of Medical Beauty Advertisements", all pointing to industry chaos.

　　On January 6, 2022, Qingdao announced ten typical cases of illegal medical aesthetics. A total of 151 cases will be investigated and punished in 2021, with a fine of 2.4723 million yuan; on January 14, 2022, the Shanghai Health and Health Commission also announced 10 typical cases of illegal medical aesthetics. In this case, a total of 8.1347 million yuan will be fined and 690,200 yuan of illegal gains will be confiscated in 2021.

　　On January 30, the "14th Five-Year Plan for the Construction of China's Medical Beauty Standard System" was released.

This industry plan announced by the China Plastic Surgery Association provides more than 50 standards, covering four aspects: industry management standards, industry technical standards, education and training standards, and industry basic standards. planning.

　　Ye Lan, vice president of the Shanghai Yangpu District People's Court, said that medical beauty institutions should truthfully describe the specific content of medical beauty projects, reasonably publicize the expected effects of medical beauty services, and promptly and comprehensively disclose the source and safety information of beauty products to consumers. Ensure that consumers have a clear and objective understanding of the medical and aesthetic services they will receive and the related risks they may face.

(Sino-Singapore Jingwei APP)